Mendes Tiago, Minori Karen, Ueta Marlene, Miguel Danilo Ciccone, Allegretti Silmara Marques
Department of Animal Biology, Post-Graduation Program in Animal Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
J Parasitol Res. 2017;2017:5056314. doi: 10.1155/2017/5056314. Epub 2017 Jan 22.
Strongyloidiasis is a parasitic neglected disease caused by the nematode affecting 30 to 100 million people worldwide. Complications, strongly associated with alcoholism, organ transplants, and HTLV-1 virus, often arise due to late diagnosis, frequently leading to patient death. Lack of preemptive diagnosis is not the only difficulty when dealing with this parasite, since there are no gold standard diagnostic techniques, and the ones used have problems associated with sensitivity, resulting in false negatives. Treatment is also an issue as ivermectin and benzimidazoles administration leads to inconsistent cure rates and several side effects. Researching new anti- drugs is a difficult task since does not develop until the adult stages in (with the exception of SCID mice), the main experimental host model. Fortunately, alternative parasite models can be used, namely, and However, even with these models, there are other complications in finding new drugs, which are associated with specific in vitro assay protocol steps, such as larvae decontamination. In this review, we highlight the challenges associated with new drug search, the compounds tested, and a list of published in vitro assay methodologies. We also point out advances being made in strongyloidiasis diagnosis so far.
粪类圆线虫病是一种由线虫引起的被忽视的寄生虫病,全球有3000万至1亿人受其影响。并发症常与酗酒、器官移植和人类嗜T淋巴细胞病毒1型(HTLV-1)相关,往往因诊断延迟而出现,常导致患者死亡。缺乏预防性诊断并非应对这种寄生虫时的唯一困难,因为没有金标准诊断技术,且所使用的技术存在灵敏度相关问题,会导致假阴性。治疗也是一个问题,因为使用伊维菌素和苯并咪唑治疗的治愈率不一致,且有多种副作用。研发新的抗寄生虫药物是一项艰巨任务,因为在主要的实验宿主模型——小鼠(严重联合免疫缺陷小鼠除外)中,该寄生虫直到成虫阶段才发育。幸运的是,可以使用替代寄生虫模型,即[此处原文缺失相关模型名称]。然而,即便有这些模型,在寻找新药时仍存在其他并发症,这些并发症与特定的体外检测方案步骤有关,如幼虫净化。在本综述中,我们强调了与新药研发相关的挑战、所测试的化合物以及已发表的体外检测方法列表。我们还指出了迄今为止粪类圆线虫病诊断方面取得的进展。